Overview

Add-on to Thiazolidinedione (TZD) Failures

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone. The safety of this treatment will also be studied

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Astra Zeneca, Bristol-Myers Squibb

Treatments:

2,4-thiazolidinedione
Dapagliflozin
Pioglitazone